Tryngolza (olezarsen) is a drug from Ionis Pharmaceuticals that lowers blood triglycerides.[1][2] Ionis expects approval of Tryngolza for severe hypertriglyceridemia, which could generate $2 billion in sales. [user] The drug is intended as an adjunct to a triglyceride-lowering diet in adults with familial chylomicronemia syndrome (FCS) and was approved by the FDA last December.[2][3][4] In the first full commercial quarter, sales reached more than $6 million, in the second quarter $19 million.[2] In a Phase III trial of Essence in patients with mild hypertriglyceridemia (TG 150–500 mg/dL) and at risk of atherosclerotic cardiovascular disease, TG reduction was achieved by 61% at 80 mg monthly and 58% at 50 mg versus placebo at six months.[1] In the Phase III CORE and CORE2 studies in patients with severe hypertriglyceridemia (sHTG), it achieved a 72% reduction in fasting TG and reduced acute pancreatic events by 85%.[2] The drug targets the apoC-III protein that regulates triglyceride metabolism and is administered by injection.[1][2] Ionis plans to submit a supplementary application for approval to the sHTG by the end of the year.[2]